title: Improved clinical outcomes with multi-modality therapy for sinonasal undifferentiated carcinoma of the head and neck.
abstract: OBJECTIVE
  To examine outcomes among patients treated for sinonasal undifferentiated carcinoma (SNUC) of the head and neck.
  
  
  METHODS
  Retrospective review.
  
  
  METHODS
  The records of 16 consecutive patients with newly diagnosed, non-metastatic SNUC were analyzed. Initial treatment consisted of: surgery alone (6 patients), surgery with post-operative chemoradiotherapy (4 patients), and primary radiation therapy with concurrent chemotherapy (6 patients).
  
  
  RESULTS
  The median survival for patients treated by surgery followed by postoperative chemoradiotherapy was 30 months compared to 7 months and 9 months for patients treated by surgery alone and upfront chemoradiotherapy, respectively (p=0.20). The 2-year locoregional control was 18% for patients treated with upfront chemoradiotherapy, 37% for patients treated with surgery alone, and 78% for patients treated with surgery plus chemoradiotherapy (p=0.49).
  
  
  CONCLUSIONS
  While the potential role of selection bias must be considered, multi-modality therapy using surgery and post-operative chemoradiotherapy yielded the most favorable outcomes for SNUC and should be recommended whenever feasible.
authors.affiliation: Department of Radiation Oncology, University of California Davis School of Medicine, Sacramento, CA, USA.
authors.forename: Emi
authors.initials: E
authors.lastname: Yoshida
authors.forename: Rony
authors.initials: R
authors.lastname: Aouad
authors.forename: Ruben
authors.initials: R
authors.lastname: Fragoso
authors.forename: D Gregory
authors.initials: DG
authors.lastname: Farwell
authors.forename: Regina
authors.initials: R
authors.lastname: Gandour-Edwards
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Donald
authors.forename: Allen M
authors.initials: AM
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008443:Maxillary Sinus / Q000601:surgery; D008444:Maxillary Sinus Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D037981:Neck Dissection; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies
chemical_list: D005047:Etoposide; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin